Give every branch a voice in what works.
A central medicines initiative becomes real through local teams. Its value depends on what happens across different branches, staffing patterns and service demands.
Our pharmacy-network direction explores how medicines intelligence can make that organisational learning more useful, from a small independent group to a national or online provider.
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Understand the difference that changes the result.
A network can share a policy while branches face different demand, available capacity and operating conditions. Those differences matter when a central team decides what to introduce and how much support it will need.
A useful comparison connects local experience with a common question. Which part of the approach worked? Where did checking or coordination increase? What depended on a particular team or setting? The aim is to understand the conditions that make a change repeatable.
Make the decision useful to the people who own it.
An owner or operations director needs a clear account of delivery and organisational effort. Clinical services and professional standards teams need to understand how the approach supports the intended service. Finance needs a view of the costs and where value would arise.
A medicines intelligence proposition should connect those needs with the branch team’s reality. The people authorising an evaluation may include central leadership, the superintendent, information governance, security and procurement, according to the organisation. Identifying the right roles early makes the proposed scope more practical.
Count the work the branch is asked to carry.
Onboarding, training, checking, questions and ongoing updates all take attention. A workflow that is convenient at headquarters can still ask too much of local teams. That burden needs to be visible in a fair evaluation.
Our development interest includes how teams understand the purpose of a change, the responsibilities it creates and the route for unresolved issues. Pharmacy staff should be able to explain where an approach helps and where it creates extra work. That feedback is valuable evidence for the next decision.
Scale the part that has earned a reason to spread.
A first network evaluation should define the process, the participating settings and measures that can be interpreted across them. It should include a realistic support model and a credible comparison with competent existing practice.
PHARMORIS is our flagship programme for the connection between evidence, decisions, implementation and value review. The network direction applies that ambition to a recurring organisational task. It asks what should be repeated, what needs local adaptation and what the evidence says about the effort of scaling.
One ambition. Different pharmacy days.
A network moves through its people. Understand the work at every branch.
Film creditsDistance makes accountability more important.
For an online provider, the medicines journey may involve a prescribing service, dispensing pharmacy, delivery organisation and other partners. The responsibilities between them need to be understood alongside the service itself.
The GPhC’s February 2025 distance-service guidance addresses risk management, communication, third-party arrangements and safe service provision for registered pharmacies in Great Britain. It provides a useful context for discussing a defined remote-provider workflow. A proposed evaluation must reflect the actual service, professional roles and relevant legal requirements.
Bring supply constraints into the conversation.
A medicines change can depend on what is available, the terms under which it can be obtained and what the organisation needs to do to introduce it. Branch operations, central supply teams and external organisations can see different parts of that problem.
Our supply-resilience direction asks how relevant constraints and uncertainty can be represented clearly enough for accountable review. Suitable data, permissions and operational participation would determine a specific evaluation. The public proposition is about making the decision clearer, rather than promising a live stock feed or an ordering integration.
A US network needs a US decision model.
In the United States, community pharmacy owners, chain leadership, health-system pharmacy teams and health plans have different organisational roles. Hospital and health-system formulary work commonly involves Pharmacy and Therapeutics processes; coverage and reimbursement decisions bring other decision-makers into view.
We would begin with a defined pharmacy-led organisational task, its local budget owner and the evidence required to judge it. A UK branch proposition cannot simply be relabelled for that setting. The implementation, purchasing and governance context is part of the work to be understood.
From service readiness to sustained value.
A pharmacy service needs more than visibility. We are exploring a review that follows readiness through completed consultations and accepted claims, then asks what value remains after delivery costs and whether it persists. The practical question: what is holding the service back, and is expansion worth it?
For a network, each stage changes the expansion question. Are teams ready to deliver? Do consultations reach completion? Are claims accepted? What does delivery actually cost? Looking across that sequence could help an owner distinguish a promising launch from a service with a repeatable operating case.
Prove the case for the next group of sites.
A defensible network case explains the intended benefit, the complete delivery effort and the conditions under which it was observed. It distinguishes a result at selected sites from an assumption about the whole estate.
The next decision might concern extending an evaluation, changing the workflow or investigating a different operational question. What matters is that leadership can see why the decision follows from the evidence. We welcome small groups, larger chains and remote providers with a specific task and an accountable team to explore.
Which medicines initiative deserves a clearer network view?
Start with the recurring task, the branches or teams involved and the decision your organisation wants to make.